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Abstract
Adult-onset Still’s disease (AOSD) is a rare systemic inﬂammatory disorder in which inﬂammasome activation plays a
pathophysiological role. In view of the inﬂammatory nature of AOSD, we investigated whether serum amyloid A (SAA) gene
polymorphisms affect the susceptibility of patients with AOSD.
Eighty-seven Japanese patients with AOSD and 200 healthy Japanese subjects were recruited in this study. The genotypes of the
-13C/T SNP in the 50-ﬂanking region of the SAA1 gene (rs12218) and two SNPs within exon 3 of SAA1 (2995C/T and 3010C/T
polymorphisms) were determined using polymerase chain reaction fragment length polymorphism (PCR-RFLP) assay in all subjects.
In AOSD patients, exons 1, 2, 3, and 10 of the MEFV gene were also genotyped by direct sequencing.
The frequency of the SAA1.3 allele was increased in AOSD patients compared with that in healthy subjects (43.1% versus 37.5%),
but the difference was not signiﬁcant. The 13T allele was more frequently observed in AOSD patients than in healthy subjects
(50.6% versus 41.0%, P= .0336). AOSD patients with the 13T allele had been treated with immunosuppressants more frequently
than those without this allele. MEFV mutations were detected in 49 patients with AOSD (49/87, 57.3%). AOSD patients with MEFV
variants frequently exhibit macrophage activation syndrome, but the difference was not signiﬁcant (34.7% versus 18.4%, P= .081).
Also, there was no signiﬁcant difference in SAA1-13C/T allele frequency between AOSD patients with and withoutMEFVmutations.
Our data shows a signiﬁcant association between T allele of rs12218 and AOSD in Japanese population.
Abbreviations: AOSD = adult onset Still’s disease, PCR-RFLP = PCR restriction fragment length polymorphism, SAA = serum
amyloid A, SNPs = single-nucleotide polymorphisms.
Keywords: adult-onset still’s disease, inﬂammasome, MEFV, polymorphisms, serum amyloid A
1. Introduction
Adult-onset Still’s disease (AOSD) is a systemic inﬂammatory
disease characterized by spiking fever, skin rash, and
arthritis.[1] Although its pathogenesis is largely unknown,[2] a
growing number of studies support the hypothesis that dysregu-
lation of inﬂammasome activation and the related overproduction
of cytokines play a pivotal role in it, similar to other auto-
inﬂammatorydiseases.[3] SerumamyloidA (SAA) is anacute-phase
reactant that is synthesized in the liver by inﬂammatory cytokines,
the level of which can increase 1000-fold during inﬂammatory
conditions.[4] Within the SAA gene cluster, only the SAA1 and
SAA2 genes encode acute-phase SAA.[5] The presence of two
single-nucleotide polymorphisms (SNPs) within exon 3 of the
SAA1 gene, 2995C/T and 3010C/T, deﬁne 3 haplotypes that
correspond to SAA1.1, SAA1.3, and SAA1.5.[6] Several studies
have shown that the development of AA amyloidosis is positively
related to the frequency of SAA1.3 alleles in the Japanese
population.[7,8] Subsequent investigations indicated that another
SNP (rs12218) in the SAA1 gene, at position -13 in the 50
regulatory region of this gene, is in linkage disequilibriumwith the
SAA1.3 allele and is closely associated with the occurrence of AA
amyloidosis in Japanese and Caucasian rheumatoid arthritis
patients.[9,10] Moreover, a functional study suggested that the T
variant at this SNP is associated with greater transcriptional
activity of the SAA1 gene.[11]
G-protein-coupled formyl peptide receptor 2 (FPR2) is one of
the receptors for SAA.[12] In addition to FPR2, several receptors
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for SAA have been identiﬁed.[13] Recent studies have suggested
that SAA may play a role in the modulation of inﬂammation and
immunity through these SAA receptors.[14] In this study, we
investigated the relationship between SAA1 gene polymorphism
and AOSD.
2. Patients and methods
2.1. Design, setting, patients, and measurements
We retrospectively evaluated 87 patients, who were diagnosed as
AOSD and be treated at the Rheumatology Units of participating
hospital group, between 2010 and 2017. The patients had all
been diagnosed with AOSD according to the Yamaguchi
criteria,[15] after exclusion of infectious, hematologic, and
inﬂammatory diseases. All patients had undergone laboratory
tests, including a complete blood count, biochemistry, urinalysis,
erythrocyte sedimentation rate (ESR) and ferritin. The demo-
graphic data of the enrolled patients, including clinical
manifestations, treatments, prognosis, and complications, were
collected using a standardized form. Each patient was assessed
for the systemic score proposed by Pouchot et al[26] for AOSD.
This score assigns 1 point to each of 12 manifestations: fever,
typical rash, pleuritis, pneumonia, pericarditis, hepatomegaly or
abnormal liver function tests, splenomegaly, lymphadenopathy,
leukocytosis > 15,000/mm3, sore throat, myalgia, and abdomi-
nal pain (maximum score: 12 points). This study was approved
by the institutional review board of the Sasebo City Hospital
institutional review board (No. 2012-A-22) and participating
hospitals. Two hundreds of healthy Japanese individuals without
pre-existing medical diseases (90 men and 110 women 14 to 64
years, with a mean age of 38.6±13.9 years) from East Japan (n=
86) and West Japan (n=114) were enrolled in the study after
obtaining informed consent.
2.2. Genotyping of SAA1 gene
TheSAA1.1, 1.3, and1.5alleles, corresponding to theT-C,C-T, and
C-C haplotypes of the C2995T (rs1136743) and C3010T
(rs1136747) polymorphisms were analyzed by the PCR-RFLP
methods.[8] The primers used for the PCR reaction were 50-GCC
AATTACATCGGCCTCAG-30 (sense) and 50-TGGCCA
AAGAATCTCTGG AT-30 (antisense). The 518-bp PCR products
were digested with restriction enzyme BclI (Promega, San Luis
Obispo, CA, USA) and BanI (Promega) and electrophoresed on a
agarose gel. The genotypes of the SAA1 -13C/T in the 50-ﬂanking
region of the SAA1 gene, (rs12218) were also determined by the
PCR–RFLPmethod.[8] The primers used for PCRwere50-ACATCT
TGTTCCCTC AGGTTG-30 (sense) and 50-GCTGTAGCT-
GAGCTGCGG-30 (antisense). The 229-bp PCR products were
subjected to the restriction enzyme AciI (BioLabs, Beverly, MA,
USA) and electrophoresed on a 12.5% polyacrylamide gel.
2.3. MEFV gene analysis
Peripheral blood samples (collected in vacutainers containing
EDTA as anticoagulant) were used for genomic DNA isolation.
Genomic DNA was isolated by the Promega Wizard Genomic
DNA Puriﬁcation Kit (Madison, WI, USA). Polymerase chain
reaction (PCR) was performed using forward and reverse primers
for each exon of theMEFV gene, as described previously.[16] The
polymerase chain reaction (PCR) products were puriﬁed and
directly sequenced using ABI 3100 Genetic Analyzer (Applied
Biosystems, Tokyo, Japan). The MEFV genetic analysis was
approved by the Ethics Committee of Fukushima Medical
University School of Medicine (2016, No. 2920).
2.4. Statistical analysis
Statistical analyses were out using SPSS version 17.0 (SPSS;
Chicago, IL, USA). Hardy-Weinberg equilibrium was assessed by
the chi-square test. Differences in the distribution of alleles
between AOSD patients and control subjects were analyzed using
the chi-square test. Differences among AOSD characteristics were
analyzed by performing aMann-Whitney’sU test or Chi-squared
test using 22 contingency tables.
3. Results
3.1. Demographic ﬁndings of enrolled AOSD patients
A total of 87 Japanese patients (18 men and 69 women) who
fulﬁlled the Yamaguchi criteria for AOSD[15] were recruited into
this study. All patients were ethnic Japanese. Routine blood tests
including tests of C-reactive protein, serum ferritin, and liver
enzymes were performed. The clinical manifestations of the
enrolled patients are shown in Table 1. Among the 87 enrolled
patients with AOSD, 69 (79.3%) were women and the mean age
at diagnosis was 49.3±19.9 years old. Among these 87 patients,
51 patients (58.6%) were treated with immunosppressants
(Cyclosporin A 38, Tacrolimus 4, Methotrexate 9).
3.2. SAA1 gene haplotypes in Japanese patients
with AOSD
A segment of the SAA1 gene with polymorphic sites was
subjected to PCR restriction fragment length polymorphism
(PCR-RFLP) analysis. Table 2 shows the frequencies of
individuals with various genotypes and alleles at the SAA1 locus
in either AOSD patients (n=87) or healthy Japanese subjects (n=
200). The frequency of the SAA1.3 allele was increased in AOSD
patients compared with that in healthy subjects (43.1% versus
37.5%), but the difference was not signiﬁcant.
3.3. Association of SAA1 13T allele with AOSD in
Japanese
The -13C/T polymorphism, in the 50-ﬂanking region of the
SAA1 gene, which is in linkage disequilibrium with the SAA1.3
Table 1
Demographic ﬁndings of enrolled AOSD patients.
Number 87
Female, n (%) 69 (79.3)
Age at onset (years) 49.3±19.9
Ferritin (ng/mL) 11251.2±16997.9
CRP (mg/dL) 12.4±8.2
ESR (mm(1h)) 71.1±30.1
Liver dysfunction, n (%) 68 (78.1)
MAS, n (%) 23 (26.4)
Initial dose of PSL (mg/day) 41.8±12.2
Steroid pulse, n (%) 55 (63.2)
Immunosuppressant, n (%) 51 (58.6)
Biologics, n (%) 26 (29.8)
Mean± standard deviation or number (%) is shown.
CRP=C-reactive protein, ESR= erythrocyte sedimentation rate, MAS=macrophage activation
syndrome, PSL=prednisolone.
AOSD= adult onset Still’s disease.
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allele, has been shown to be associated with susceptibility to
AA amyloidosis in Japanese RA patients. We thus analyzed the
-13C/T polymorphisms in AOSD patients and healthy Japanese
subjects. The observed genotype frequencies did not differ from
the expected frequencies of the genotypes under the assumption
of Hardy–Weinberg equilibrium (data not shown). Allele
frequencies of -13C/T differed between the 2 groups (Table 3),
with the 13T allele being signiﬁcantly more common in
AOSD patients than in healthy subjects (50.6% versus 41.0%,
P= .0336). This suggests that the 13T allele is associated with
susceptibility to AOSD in the Japanese population. To evaluate
the potential correlations of -13C/T alleles with the clinical
manifestations of AOSD, we stratiﬁed the AOSD patients
according to the presence of the 13T allele (Table 4). AOSD
patients with this allele were found to have been treated more
frequently (64.7% versus 36.8%, P= .029) with immunosup-
pressants (Cyclosporin A 33, Tacrolimus 2, Methotrexate 9),
but there was no signiﬁcant difference in the other clinical
manifestations. We also compared the systemic score according
to the genotypes of SAA -13C/T among AOSD patients. As
demonstrated in Figure 1, we could not ﬁnd a signiﬁcant
difference in systemic score according to the genotype SAA
-13C/T allele in Japanese patients with AOSD.
3.4. MEFV variant analysis
All AOSD patients were successfully genotyped for the MEFV
gene. MEFV variants were identiﬁed in 46 AOSD patients
(57.6%), the distribution of which is shown in Table 5. We
stratiﬁed the AOSD patients according to the presence or absence
of MEFV variants, and then compared the clinical features
between these groups (Table 6). Although there was no
statistically signiﬁcant difference, AOSD patients with MEFV
variants were more frequently associated with macrophage
activation syndrome (34.7% versus 18.4%, P= .092) and the
initial doses of prednisolone were higher compared with those
without MEFV variants (35.9±12.8mg/day versus 31.8±11.2
mg/day, P= .081). We also compared the frequencies of -13C/T
polymorphisms between the AOSD patients stratiﬁed according
to the presence of MEFV variants, but no signiﬁcant differences
were found (Table 7).
4. Discussion
A major acute-phase reactant, SAA, is produced when the
immune system senses potential danger signals including trauma,
infection, and severe stress.[17] Previous studies accumulated
substantial evidence that SAA is involved in inﬂammatory
disorders including autoinﬂammatory diseases.[18] SAA has
proinﬂammatory activities, including those involving cell migra-
tion and phagocytosis.[19] It is also considered to be a danger
signal that activates inﬂammasomes.[20] Speciﬁcally, SAA is
capable of activating NOD-like receptor family pyrin domain
containing 3 (NLRP3) inﬂammasome and subsequent IL-1b
production,[21] which play important roles in the pathogenesis of
AOSD. Therefore, it is possible that SAA is important in the
pathogenesis of autoinﬂammatory diseases including AOSD.
Evidence has also been presented that the risk of AOSD is
inﬂuenced by polymorphisms in proinﬂammatory genes includ-
ing cytokines and components of the innate immune system.[22]
In this study, we found that polymorphisms of the SAA1 gene
were associated with the susceptibility to AOSD in the Japanese
population. We demonstrated that the frequency of the T allele at
position 13 in the SAA1 gene (rs12218) was signiﬁcantly
increased in AOSD patients compared with that in healthy
subjects. Previous studies also demonstrated the strong linkage
disequilibrium between the SAA1.3 allele and the SAA1 13T
Table 2
SAA1 genotype and allele frequency in the AOSD patients and
controls.
AOSD patients Control
Genotypes n=87 (%) n=200 (%)
1.1/1.1 8 (9.2) 24 (12.0)
1.1/1.3 25 (28.7) 49 (24.5)
1.1/1.5 12 (13.8) 39 (19.5)
1.3/1.3 14 (16.1) 27 (13.5)
1.3/1.5 22 (25.3) 47 (23.5)
1.5/1.5 6 (6.9) 14 (7.0)
AOSD patients Control
Alleles n=174 (%) n=400 (%) P value
1.1 53 (30.5) 136 (34.0) .4068
1.3 75 (43.1) 150 (37.5) .2063
1.5 46 (26.4) 114 (28.5) .6124
SAA1; Serum amyloid A1. Chi-square test was used to examine differences of genotype and allele
frequencies between AOSD patients and healthy subjects.
AOSD=adult onset Still’s disease.
Table 3
Genotype and allele frequencies of13C/T SAA1 in AOSDpatients
and the healthy subjects.
AOSD patients Healthy subjects
n=87 (%) n=200 (%) x2 P value
Genotypes at 13C/T SAA1
C/C 19 (21.8) 67 (33.5)
C/T 48 (55.1) 102 (51.0)
T/T 20 (22.9) 31 (15.5)
Alleles at 13C/T SAA1
C 86 (49.4) 236 (59.0)
T 88 (50.6) 164 (41.0) 4.513 .0336
AOSD=adult onset Still’s disease, Genotypes and allele frequency are shown in parenthesis (%).
Association was tested by x2 test using 22 contingency tables.
Table 4
Demographic and clinical features of AOSD patients with or
without -13 T allele.
C/C C/T, T/T
Demographic/clinical features (n=19) (n=68) P value
Age, years (SD) 51.12 (21.9) 53.50 (28.9) .513
Onset age, years (SD) 47.47 (22.3) 49.88 (19.3) .662
Gender (Female/Male) 14/5 55/13 .493
CRP mg/dl, (SD) 12.34 (8.3) 11.78 (8.3) .442
Ferritin ng/ml, (SD) 7292.2 (12535.2) 11199.2 (17867.8) .969
Liver dysfunction, (%) 13 (68.4%) 55 (80.9%) .245
MAS, (%) 6 (31.5%) 18 (26.5%) .659
Initial dose of PSL mg/dl, (SD) 31.8 (14.6) 34.8 (11.8) .679
Steroid pulse therapy, (%) 6 (31.5%) 26 (38.2%) .594
Immunosuppressants, (%) 7 (36.8%) 44 (64.7%) .029
Association was tested between AOSD patients with or without13 T allele by Chi-squared test using
22 contingency tables or Mann-Whitney’s U test.
CRP=C-reactive protein, MAS=macrophage activation syndrome, PSL=prednisolone, SD=
standard deviation.
AOSD= adult onset Still’s disease.
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allele in the Japanese population.[9] Our data also indicate that
the allele frequency of SAA1.3 was increased in AOSD patients
compared with that in healthy controls, although this did not
reach statistical signiﬁcance.
The overproduction of IL-1b is responsible for a variety of
autoinﬂammatory disorders, including AOSD.[23] Recent studies
have shown that SAA activates the NLRP3 inﬂammasome and
subsequent IL-1b production in innate immune cells,[24]
suggesting a link between SAA and autoinﬂammatory diseases.
Figure 1. Systemic scores of AOSD patients among the different genotypes of SAA1-13C/T allele. The values of the systemic scores of each AOSD patients
stratiﬁed by the genotypes of SAA1-13C/T allele are shown. Values are expressed as mean±standard deviation. NS; not signiﬁcant. AOSD=adult onset Still’s
disease.
Table 5
MEFV genotypes of AOSD patients.
Mutations Number of patients (%) (n=87)
M694I/normal 2 (2.3)
G632S/E408Q 1 (1.1)
P369S/R408Q 4 (4.6)
E148Q/P369S 1 (1.1)
E148Q/E148Q/P369S/R408Q 1 (1.1)
L110P/E148Q/E148Q/P369S/R408Q 1 (1.1)
E148Q/P369S/R408Q 2 (2.3)
E148Q/R202Q 1 (1.1)
R202Q/normal 3 (3.4)
E148Q/normal 19 (21.8)
E148Q/E148Q 2 (2.3)
L110P/E148Q 6 (6.9)
L110P/E148Q//E148Q 2 (2.3)
L110P/E148Q//R202Q 1 (1.1)
L110P/L110P/E148Q//E148Q 1 (1.1)
E84K/normal 1 (1.1)
E84K/L110P/E148Q 1 (1.1)
Normal 38 (43.7)
AOSD=adult onset Still’s disease.
Table 6
Demographic and clinical features of AOSD patients with or
without MEFV variants.
MEFV variants
(+) n=49
MEFN variants
() n=38
Demographic/clinical features (n=49) (n=38) P value
Age years, (SD) 53.3 (10.6) 53.1 (19.9) .687
Onset age years, (SD) 48.2 (19.2) 50.9 (20.9) .598
Gender (Female/Male) 38/11 31/7 .645
CRP mg/dl, (SD) 11.4 (7.9) 12.6 (8.7) .459
Ferritin ng/ml, (SD) 11808.7 (20164.5) 9211.6 (14374.5) .528
Liver dysfunction, (%) 38 (77.6%) 30 (78.9%) .875
MAS, (%) dctivation syndrome (%) 17 (34.7%) 7 (18.4%) .092
Initial dose of PSL mg/dl, (SD) 35.9 (12.8) 31.8 (11.2) .081
Steroid pulse therapy, (%) 32 (65.3%) 23 (60.5%) .646
Immunosuppressant, (%) 30 (61.2%) 21 (55.3%) .575
Biologics, (%) 14 (28.6%) 12 (31.6%) .761
Association was tested between AOSD patients with or without MEFV variants by Chi-squared test
using 22 contingency tables or Mann-Whitney’s U test. CRP=C-reactive protein, MAS=
macrophage activation syndrome, PSL=prednisolone, SD= standard deviation.
AOSD= adult onset Still’s disease.
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SNPs identiﬁed in the promoter region of the SAA1 gene have
been shown to be associated with a predisposition to AA
amyloidosis.[8,9] The mechanisms by which SAA1 gene polymor-
phism (-13C/T, rs12218) may be associated with AOSD are
unknown. Moriguchi et al demonstrated that a C/T switch at -13
of SAA1 gene (-13C/T) is associated with increased transcription
activity of this gene correlating susceptibility to AA amyloidosis
in Japanese patients with rheumatoid arthritis. They found 4
major haplotypes of SAA1 promoter based on 3 SNPs at -61, -13,
and -2 of the SAA1 promoter region and designed them -14C1 (C-
C-G), -13C2 (G-C-G), -13C3 (G-C-A), and -13T (C-T-G). They
demonstrated that 13T promoter exhibited greater transcrip-
tional activity compared to other cis-regulating elements
promoter haplotypes -13C1, -13C2, and -13C3 in luciferase
reporter gene assays under IL-1b or IL-6 stimulation. The serum
concentration of A-SAA to C-reactive protein (CRP) were
signiﬁcantly higher in subjects carrying SAA1.5 allele than in
those carrying1.3 allele. The data from luciferase reporter assay
seem inconsistent with these laboratory data. However, an
increased transcriptional ability of A-SAA does not necessarily
result in a serum SAA concentrations due to other factors, such as
A-SAA stability and degradation may inﬂuence the serum
concentrations of A-SAA.
It has been reported that SAA1 polymorphisms are associated
with the risk of inﬂammatory disorders.[5] The TT genotype is
associated with an increased risk for carotid artery intima-media
thickness in obese individuals.[25] Interestingly, AOSD patients
with the13T allele in this study were found to have been treated
with immunosuppressants more frequently than those without
this allele. These ﬁndings suggest that the T allele may confer
more proinﬂammatory phenotypes, including cytokine produc-
tion, in AOSD patients. In comparison, the CC genotype of
vs12218was found to bemore common among patients suffering
from coronary artery disease.[26] Because of the presence of
multiple receptors, the effects of SAA are pleiotropic and may not
be categorized simply as being proinﬂammatory.
We previously reported that individuals carrying the T allele of
-13C/T (rs12218) have increased susceptibility to familial
Mediterranean fever (FMF), a hereditary autoinﬂammatory
disease.[27] The signiﬁcance of the difference in the T-allele
frequency compared with that in controls is greater in FMF than
in AOSD, a nonhereditary autoimmune disease. We could not
provide a plausible explanation for this. We aimed to determine
whether any SNPs within the SAA1 gene conferred an increased
risk of susceptibility to AOSD. However, collection of AOSD
would require collaboration with multiple centers and there is the
possibility that the numbers of patients involved would still be
small. We assumed that there is a shared genetic basis for AOSD;
however, the clinical phenotype of AOSD is heterogeneous.[3]
This complexity may have contributed to the less signiﬁcant
association between SAA1 gene polymorphisms and AOSD,
compared with that for FMF, a more categorized autoinﬂam-
matory disorder.
MEFV gene mutations/polymorphisms have been implicated
in more than 1 genetic autoinﬂammatory disease, FMF.[28]
Therefore, we considered that it would be reasonable for the
MEFV gene to also be associated with AOSD. The allele
frequencies of common polymorphisms in exons 2 and 3 of the
MEFV gene in AOSD patients (R408Q, 3.3%; P369S, 3.3%;
E148Q, 23.7%) were similar to those of healthy Japanese
subjects, as described previously.[29] Therefore, MEFV gene
polymorphisms may not be involved in the susceptibility to
AOSD. However, these genetic variations may be related to the
clinical manifestations of AOSD. Although no statistically
signiﬁcant results were obtained, AOSD patients carrying
MEVF variants showed a tendency to be associated with MAS
and to be treated with higher doses of steroids than those
without these variants. These ﬁndings suggest that variation
in autoinﬂammatory genes may modify the disease phenotype
of AOSD.
Our study has some limitations, one of which was the relatively
small number of studied subjects. This case–control study for
SAA1 gene polymorphisms may have been underpowered due to
the rarity of patients with AOSD. Another limitation of this study
is that the examined subjects were ethnically Japanese; hence,
caution should be exercised when extrapolating our results to
other ethnic groups. In the present study, we did not examine the
differences in circulating SAA levels between each genotype,
which was a limitation of our study.
5. Conclusions
In conclusion, we suggest that the SNPs in the promoter region of
SAA1 gene (-13C/T) may correlate with AOSD in the Japanese
population. Further studies are necessary to determine, which are
the predominant SNPs with the susceptibility to AOSD in various
ethnic population.
Author contributions
Conceptualization: Atshushi Kawakami.
Data curation: Tomoyuki Asano, Shuzo Sato, Hiroko Kobaya-
shi, Hiroshi Watanabe, Eiji Suzuki, Tadashi Nakamura,
Toshimasa Shimizu, Masataka Umeda, and Fumiaki Nonaka.
Formal analysis: Kiyoshi Migita, Tomoyuki Asano, and
Tomohiro Koga.
Investigation: Kiyoshi Migita, Hiroshi Furukawa, and Tomohiro
Koga.
Methodology: Hiroshi Furukawa and Tomohiro Koga.
Project administration: Kiyoshi Migita, Tomohiro Koga, Yuki-
taka Ueki, Katsumi Eguchi, and Atshushi Kawakami.
Supervision: Yukitaka Ueki, Katsumi Eguchi, and Atshushi
Kawakami.
Validation: Tomohiro Koga.
Writing – original draft: Makiko Yashiro.
Table 7
Frequencies at 13C/T alleles in AOSD patients with or without MEFV variants.
AOSD with MEFV variants AOSD without MEFV variants
Alleles at 13 C/T (n=49) (n=38) x2 P value
C 51 (52.0%) 35 (46.1%)
T 47 (53.1%) 41 (53.9%) 0.614 .433
Allele carrier frequencies are shown in parenthesis (%). Association was tested by x2 test.
AOSD=adult onset still’s disease.
Yashiro et al. Medicine (2018) 97:49 www.md-journal.com
5
Writing – review, and editing: Kiyoshi Migita and Hiroshi
Furukawa.
References
[1] Castañeda S, Blanco R, González-Gay MA. Adult-onset Still’s disease:
advances in the treatment. Best Pract Res Clin Rheumatol 2016;30:222–38.
[2] Efthimiou P, Georgy S. Pathogenesis and management of adult-onset
Still’s disease. Semin Arthritis Rheum 2006;36:144–52.
[3] Gerfaud-Valentin M, Jamilloux Y, Iwaz J, et al. Adult-onset Still’s
disease. Autoimmun Rev 2014;13:708–22.
[4] Marhaug G, Dowton SB. Serum amyloid A: an acute phase
apolipoprotein and precursor of AA amyloid. Baillieres Clin Rheumatol
1994;8:553–73.
[5] Sun L, Ye RD. Serum amyloid A1: structure, function and gene
polymorphism. Gene 2016;583:48–57.
[6] Baba S, Masago SA, Takahashi T, et al. A novel allelic variant of serum
amyloid A, SAA1 gamma: genomic evidence, evolution, frequency, and
implication as a risk factor for reactive systemic AA-amyloidosis. Hum
Mol Genet 1995;4:1083–7.
[7] Nakamura T, Higashi S, Tomoda K, et al. Signiﬁcance of SAA1.3 allele
genotype in Japanese patients with amyloidosis secondary to rheumatoid
arthritis. Rheumatology 2006;45:43–9.
[8] Ajiro J, Narita I, Sato F, et al. SAA1 gene polymorphisms and the risk of
AA amyloidosis in Japanese patients with rheumatoid arthritis. Mod
Rheumatol 2006;16:294–9.
[9] Moriguchi M, Terai C, Kaneko H, et al. A novel single-nucleotide
polymorphism at the 50-ﬂanking region of SAA1 associated with risk of
type AA amyloidosis secondary to rheumatoid arthritis. Arthritis Rheum
2001;44:1266–72.
[10] Yamada T, Okuda Y, Takasugi K, et al. An allele of serum amyloid A1
associated with amyloidosis in both Japanese and Caucasians. Amyloid
2003;10:7–11.
[11] MoriguchiM, KanekoH, Terai C, et al. Relative transcriptional activities
of SAA1 promoters polymorphic at position -13(T/C): potential
association between increased transcription and amyloidosis. Amyloid
2005;12:26–32.
[12] Liang TS, Wang JM, Murphy PM, et al. Serum amyloid A is a
chemotactic agonist at FPR2, a low-afﬁnity N-formylpeptide receptor on
mouse neutrophils. Biochem Biophys Res Commun 2000;270:331–5.
[13] Eklund KK, Niemi K, Kovanen PT. Immune functions of serum amyloid
A. Crit Rev Immunol 2012;32:335–48.
[14] Ye RD, Sun L. Emerging functions of serum amyloid A in inﬂammation. J
Leukoc Biol 2015;98:923–9.
[15] Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for
classiﬁcation of adult Still’s disease. J Rheumatol 1992;19:424–30.
[16] Tanaka M, Migita K, Miyashita T, et al. Coexistence of familial
Mediterranean fever and Sjögren’s syndrome in a Japanese patient. Clin
Exp Rheumatol 2007;25:792.
[17] Jensen LE, Whitehead AS. Regulation of serum amyloid A protein
expression during the acute-phase response. Biochem J 1998;334:489–
503.
[18] Cunnane G. Amyloid precursors and amyloidosis in inﬂammatory
arthritis. Curr Opin Rheumatol 2001;13:67–73.
[19] GouwyM, De BuckM, Pörtner N, et al. Serum amyloid A chemoattracts
immature dendritic cells and indirectly provokes monocyte chemotaxis
by induction of cooperating CC and CXC chemokines. Eur J Immunol
2015;45:101–12.
[20] Yu N, Liu S, Yi X, et al. Serum amyloid A induces interleukin-1b
secretion from keratinocytes via the NACHT, LRR and PYD
domains-containing protein 3 inﬂammasome. Clin Exp Immunol
2015;179:344–53.
[21] Niemi K, Teirilä L, Lappalainen J, et al. Serum amyloid A activates the
NLRP3 inﬂammasome via P2X7 receptor and a cathepsin B-sensitive
pathway. J Immunol 2011;186:6119–28.
[22] Chen DY, Chen YM, Chen HH, et al. Functional association of
interleukin 18 gene -607 (C/A) promoter polymorphisms with disease
course in Chinese patients with adult-onset Still’s disease. J Rheumatol
2009;36:2284–9.
[23] Efthimiou P, Kontzias A, Ward CM, et al. Adult-onset Still’s disease: can
recent advances in our understanding of its pathogenesis lead to targeted
therapy? Nat Clin Pract Rheumatol 2007;3:328–35.
[24] Migita K, Izumi Y, Jiuchi Y, et al. Serum amyloid A induces NLRP-3-
mediated IL-1b secretion in neutrophils. PLoS One 2014;9:e96703.
[25] Xie X, Ma YT, Yang YN, et al. Polymorphisms in the SAA1/2 gene
are associated with carotid intima media thickness in healthy Han
Chinese subjects: the cardiovascular risk survey. PLoS One 2010;5:
e13997.
[26] Wang BY, Hang JY, Zhong Y, et al. Association of genetic
polymorphisms of SAA1 (rs12218) with myocardial infarction in a
Chinese population. Genet Mol Res 2014;13:3693–6.
[27] Migita K, Agematsu K, Masumoto J, et al. The contribution of SAA1
polymorphisms to Familial Mediterranean fever susceptibility in the
Japanese population. PLoS One 2013;8:e55227.
[28] Ben-Chetrit E, Peleg H, Aamar S, et al. The spectrum of MEFV clinical
presentations–is it familial Mediterranean fever only? Rheumatology
(Oxford) 2009;48:1455–9.
[29] Migita K, Nakamura T, Maeda Y, et al. MEFV mutations in Japanese
rheumatoid arthritis patients. Clin Exp Rheumatol 2008;26:1091–4.
Yashiro et al. Medicine (2018) 97:49 Medicine
6
